Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JT21-25
- Development stage
- Unknown
- Lead developer
- Jiangxi University of Traditional Chinese Medicine
- Modality
- Small Molecules
01
Overview
JT21-25: sourced facts only. name: "Here, we reported the discovery of a promising compound 9h (JT21-25) containing quinoline structures as a potent small molecule inhibitor of ASK1." [PMID:38325130]; target: "Here, we reported the discovery of a promising compound 9h (JT21-25) containing quinoline structures as a potent small molecule inhibitor of ASK1." [PMID:38325130]; developer: "College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330004, PR China." [PMID:38325130]; modality: "Here, we reported the discovery of a promising compound 9h (JT21-25) containing quinoline structures as a potent small molecule inhibitor of ASK1." [PMID:38325130]
02
Targets
MAP3K5 (ASK1)
Beyond the preview
Go deeper on JT21-25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JT21-25.